07.05.2018 | Klinische Studien

Janus-Kinase-Inhibitor Baricitinib bei rheumatoider Arthritis

Randomized, Double-Blind, Placebo- and Active-Controlled, Phase 3 Study Evaluating the Efficacy and Safety of Baricitinib in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Methotrexate Therapy (RA-BEAM)

verfasst von: Prof. Dr. R. Alten, S. Nitschmann

Erschienen in: rheuma plus | Ausgabe 3/2018